Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors
US-10562899-B2 · Feb 18, 2020 · US
US12582604B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12582604-B2 |
| Application number | US-202017423600-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 23, 2020 |
| Priority date | Jan 25, 2019 |
| Publication date | Mar 24, 2026 |
| Grant date | Mar 24, 2026 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Disclosed herein is a physically stable solid dispersion comprising Compound 1, i.e., the B-RAF kinase dimer inhibitor 1-((1S, 1aS, 6bS)-5-((7-oxo-5, 6, 7, 8-tetrahydro-1, 8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropa [b] benzofuran-1-yl)-3-(2, 4, 5-trifluorophenyl) urea and a specific stabilizing polymer, the method for preparing the same, and the uses of the solid dispersion. Also disclosed herein is the crystalline form of Compound 1.
Opening claim text (preview).
What is claimed is: 1 . A stable amorphous solid dispersion comprising Compound 1 and a stabilizing polymer, wherein Compound 1 is 1-((1S,1aS,6bS)-5-((7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-1-yl)-3-(2,4,5-trifluorophenyl) urea, and Compound 1 is molecularly dispersed within a polymer matrix formed by the stabilizing polymer in its solid state, wherein the stabilizing polymer is hydroxypropyl methylcellulose acetate succinate, type LF (HPMCAS-LF), and the weight ratio of Compound 1 in the form of freebase and the polymer is 1:4, and wherein HPMCAS-LF has 5.0-9.0% of acetyl group and 14.0-18.0% of succinoyl group. 2 . The stable amorphous solid dispersion according to claim 1 , wherein the stable amorphous solid dispersion has a drug-loading content of Compound 1 ranging from 10% w/w to 40% w/w. 3 . The stable amorphous solid dispersion according to claim 1 , wherein the stable amorphous solid dispersion has a glass transition temperature ranging from 110-115° C. 4 . The stable amorphous solid dispersion according to claim 1 , wherein the stable amorphous solid dispersion is formulated into an orally administrated formulation.
Ortho-condensed systems · CPC title
Crystalline forms, e.g. polymorphs · CPC title
Cellulose; Derivatives thereof · CPC title
the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine · CPC title
Antineoplastic agents · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.